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mTOR Regulation of Lymphoid 
Cells in immunity to Pathogens
Rachael Keating and Maureen Ann McGargill*
Department of Immunology, St. Jude Children’s Research Hospital, Memphis, TN, USA
Immunity to pathogens exists as a fine balance between promoting activation and expan-
sion of effector cells, while simultaneously limiting normal and aberrant responses. These 
seemingly opposing functions are kept in check by immune regulators. The mechanistic 
target of rapamycin (mTOR) is a serine/threonine kinase that senses nutrient availability 
and, in turn, regulates cell metabolism, growth, and survival accordingly. mTOR plays 
a pivotal role in facilitating immune defense against invading pathogens by regulating 
the differentiation, activation, and effector functions of lymphoid cells. Here, we focus 
on the emerging and sometimes contradictory roles of mTOR in orchestrating lymphoid 
cell-mediated host immune responses to pathogens. A thorough understanding of how 
mTOR impacts lymphoid cells in pathogen defense will provide the necessary base for 
developing therapeutic interventions for infectious diseases.
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The mechanistic target of rapamycin (mTOR) is an evolutionarily conserved serine/threonine 
kinase that is ubiquitously expressed in immune cells. mTOR integrates multiple environmental 
signals to regulate diverse cellular processes including protein translation, cell growth, proliferation, 
metabolism, migration, and survival. Accordingly, mTOR plays a key role in multiple components 
of both myeloid and lymphoid cell differentiation, activation, and acquisition of effector functions. 
Through regulation of these key mechanisms, mTOR has an essential role in generating and regulat-
ing immune cells to combat pathogens.
The emerging view describes mTOR not as a single trigger for a linear cascade of events, but rather 
as a multifunctional orchestrator of diverse immune responses. In this review, we detail the current 
understanding of mTOR as a multifaceted regulator of immunity to pathogens through its impact 
on lymphoid cells. Specifically, we describe mTOR regulation of natural killer (NK) cells, invariant 
natural killer T (iNKT) cells, CD8 and CD4 T cells, and B cells during immunity to pathogens. The 
regulation of myeloid cells has been extensively reviewed recently (1). We also explore how mTOR 
inhibition may be utilized to enhance immunity to pathogens and discuss implications for vaccine 
design.
mTOR COMPLeXeS AND SiGNALiNG CASCADeS
Mechanistic target of rapamycin functions as two signaling complexes in mammalian cells: mTOR 
complex 1 (mTORC1) and mTOR complex 2 (mTORC2) (Figure 1). mTORC1 includes a scaffolding 
protein, regulatory-associated protein of mTOR (Raptor), DEP-containing mTOR interacting pro-
tein (Deptor), mammalian lethal with Sec13 protein (mLST8), and the Proline-Rich AKT substrate 
(PRAS40). Similarly, mTORC2 also comprises mTOR, Deptor, and mLST8, with the addition of the 
scaffold protein Raptor-independent Companion of TOR (Rictor), the Protein observed with Rictor 
(Proctor), and the mammalian stress activated protein kinase-interacting protein 1 (mSIN1).
FiGURe 1 | Signaling cascades promoting mTOR activation. mTOR regulates multiple cellular processes via two distinct complexes: mTORC1 and mTORC2. 
Growth factors, TCR engagement, costimulation, and cytokines all contribute to PI3K activation, which leads to the recruitment of Akt to the membrane, where it is 
phosphorylated at position threonine 308. Activated Akt then phosphorylates the TSC1/TSC2 inhibitory complex, which releases Rheb and induces accumulation of 
Rheb-GTP to promote mTORC1 activity. Rapamycin inhibits mTOR by binding to the intracellular partner, FKBP12, which directly inhibits mTORC1. Upstream 
regulation of mTORC2 is less known, but is downstream of PI3K activation. Association with ribosomes regulates mTORC2 activation. mTORC2 is typically 
regarded as insensitive to rapamycin; however, prolonged rapamycin treatment can reduce mTORC2 activity. Arrows and bars represent activation and inhibition, 
respectively. Dashed lines indicate that the exact mechanism is unknown.
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mTOR complex 1 is activated in response to various 
 extracellular stimuli including nutrients, growth factors, stress, 
cytokines, and antigen receptor signaling. When nutrients and 
these stimuli are readily available, mTORC1 activity is high, 
and energy-demanding cellular processes such as translation 
and ribosomal biogenesis are promoted. Extracellular stimuli 
activate mTORC1 by triggering a signaling cascade through 
PI3 kinase (PI3K) and the protein kinase, Akt. Akt then phos-
phorylates the mTORC1 repression factor, consisting of tuber-
ous sclerosis complex 1 (TSC1) and TSC2. Phosphorylation of 
the TSC complex prevents it from inhibiting Rheb, which is 
essential for mTORC1 activation. Additionally, mTORC1 can 
also be activated in a TSC-independent process, whereby Akt 
blocks inhibition of mTORC1 by phosphorylating PRAS40 to 
stabilize the mTOR–Raptor interaction (2, 3). Activation of 
mTORC1 leads to phosphorylation of p70–S6 kinase (S6K) and 
the eukaryotic initiation factor 4E-binding protein (4E-BP1), 
which helps regulate translation (4–6). mTORC1 signaling also 
increases the rate of glycolysis by inducing the expression of 
HIF-1α and c-Myc. Conversely, mTORC1 activity is inhibited 
when nutrient-associated cues are lacking. For example, 
in response to a decrease in the ATP/ADP ratio, the AMP-
activated protein kinase (AMPK) becomes activated, and in 
turn, inhibits mTOR activity by phosphorylating TSC2 or 
Raptor.
Activation of mTORC2 is not as well defined as mTORC1. 
Similar to mTORC1, activation of mTORC2 occurs downstream 
of P13K. However, activation of mTORC1 occurs downstream 
of Akt following phosphorylation at threonine 308 (T308), while 
mTORC2 acts upstream of Akt by phosphorylating serine 473 
of Akt (S473). In contrast to mTORC1 activation, mTORC2 
activation occurs independent of protein synthesis, but instead, 
relies on association with the ribosome (7). Activation of Akt by 
mTORC2 also leads to phosphorylation and inhibition of FOXO1 
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and FOXO3 (8). In addition to Akt, mTORC2 also activates 
serum glucocorticoid-regulated kinase 1 (SGK1) and protein 
kinase C alpha (PKCα). Signaling via mTORC2 is important 
for reorganization of the cytoskeleton through activation of 
RhoA GTPase and promoting cell survival by upregulating anti-
apoptotic proteins (7, 9).
Much of the role and function of mTOR has been ascertained 
with rapamycin, a small molecule drug derived from Streptomyces 
hygroscopicus. Rapamycin binds a 12-kDa Fk506-binding pro-
tein (FKBP12) to form the rapmycin–FKBP12 complex, which 
binds mTOR and inhibits formation of the mTORC1 complex 
(10). Prolonged rapamycin exposure also inhibits mTORC2 
(11). However, mTORC2 is typically regarded as insensitive to 
rapamycin. Use of knock-out mice, in particular, mice with a 
conditional deletion of Raptor, Rictor, Rheb, or Tsc, which are 
critical components of mTORC1 and mTORC2 complexes, have 
also greatly advanced our understanding of mTOR signaling 
pathways and function (Table 1).
Several pathways regulate activation of mTORC1 and 
mTORC2. When energy levels are low, mTORC1 is inacti-
vated, and FOXO transcribes Rictor, promoting formation of 
mTORC2, which phosphorylates Akt S473 (12). Transcription 
of Rictor and subsequent phosphorylation of Akt S473 requires 
mTORC1 inhibition (13). Similarly, while mTORC1 activates 
protein synthesis and S6K, S6K activity can repress Rictor 
and mTORC2 function. In addition, recent studies highlight 
a positive feedback loop between Akt and mTORC2 via SIN1 
phosphorylation, whereby Akt is activated following PDK1 
phosphorylation. Next, Akt phosphorylates SIN1, enhancing 
mTORC2 activity, which then promotes phosphorylation and 
complete activation of Akt (14).
Pathogens can also influence activation of the mTOR pathway. 
mTORC1 regulates translation by phosphorylating 4E-BP1, 
which releases it from the 5′ cap-binding protein, eukaryotic 
translation initiation factor 4E (eIF4E) allowing translation to 
proceed (4–6). Pathogens that are dependent on the host’s cellular 
5′ cap-dependent translation must therefore maintain mTOR 
activity, or bypass the need for mTOR-mediated phosphorylation 
of 4E-BP1 to enable the translation complex to form. Indicative 
of the former approach, human papillomavirus (HPV) uses two 
early proteins, E6 and E7, to activate mTOR signaling, which 
phosphorylates and inactivates 4E-BP1 to support viral cap-
dependent protein synthesis (15, 16). Similarly, Epstein–Barr 
virus (EBV) activates cap-dependent translation using a viral 
protein, LMP2A, to activate mTORC1 (17). Adenovirus also uses 
viral proteins (e4-ORF1 and e4-ORF4) to mimic stimulatory 
signals and activate mTORC1 activity in the absence of nutrients 
or growth factors to maintain translation of viral proteins (18). 
Bacterial pathogens including Listeria monocytogenes (L. mono-
cytogenes) and Staphylococcus aureas can also activate mTOR to 
promote IL-10 production and increase their survival in the host 
(19). Alternatively, some pathogens have evolved mechanisms to 
bypass mTORC1 activity. For example, human cytomegalovirus 
(HCMV) bypasses mTORC1 activity by directly phosphorylating 
4E-BP1 and eIF4G to maintain the activity of the translation com-
plex (20). In contrast, some pathogens such as Leishmania major 
have proteases that block mTOR activation, which suppresses 
the type 1 IFN response, allowing the pathogen to survive within 
cells (21). Hence, a pathogen’s translation requirements and the 
ability to resolve these requirements will influence whether the 
pathogen tries to enhance, bypass, or suppress mTOR activity, 
and in turn, will influence the counter approach by the host 
immune response.
mTOR ReGULATiON OF AUTOPHAGY iN 
HOST DeFeNSe
Mechanistic target of rapamycin regulates cell processes in 
response to nutrient availability. A key component of cellular 
control by mTOR is through regulation of autophagy, which is an 
essential process in all myeloid and lymphoid cells. Autophagy 
facilitates turnover of unnecessary or damaged cellular compo-
nents. These cellular components are surrounded by a double-
membraned vesicle, targeted to a lysome, degraded, and then 
recycled. This process allows cells to survive under stress. When 
energy sources are low, mTOR activity is low, biosynthesis is 
attenuated, and autophagy is upregulated to recycle nutrients, 
rather than synthesize new material. This prevents translational 
arrest and cell death. Conversely, when energy and nutrients are 
readily available, mTOR is active and signals downstream path-
ways to generate new cellular material to promote cell growth 
and proliferation, while suppressing autophagy. Basal autophagy 
levels are essential for homeostatic clearance of protein aggre-
gates and damaged organelles (22). Basal autophagy is regulated 
independent of mTOR; however, mTOR suppresses autophagy 
induction above basal levels (23). Regulation of autophagy by 
mTOR provides an interface for both pathogen assault and host 
defense, as intracellular pathogens compete with the host for 
energy and resources.
Stimuli triggered by pathogen infection can induce autophagy 
above basal levels to destroy intracellular pathogens, while 
simultaneously increasing the cell surface presentation of micro-
bial antigens to stimulate the immune response. For example, 
infection with the bacteria, Shigella flexneri, causes amino acid 
starvation and subsequent downregulation of mTOR to induce 
autophagy (24). The adaptation of the immune system to detect 
and respond to intracellular pathogens has simultaneously 
provoked evolution of some pathogens to circumvent autophagy 
induction. Indeed, HSV-1 and HSV-2 prevent induction of 
autophagy to evade immune defense mechanisms (22, 25, 26). 
Similarly, L. monocytogenes and Salmonella attempt to subvert 
induction of autophagy by reactivating mTOR to downregulate 
the immune response (24, 27). Therefore, these pathogens hijack 
and maintain basal levels of autophagy to exploit host energy sup-
plies and nutrients for their own replication. In such situations, 
it is beneficial for host defense mechanisms to inhibit mTOR and 
induce autophagy above basal levels.
In contrast, autophagy induction can benefit some pathogens 
by supporting their replication. Multiple subtypes of influenza A 
virus induce autophagy and autophagic cell death by suppress-
ing mTOR to promote replication (28, 29). Hence, autophagy 
inhibitors may limit influenza virus infection. Datan et al. also 
reported that influenza virus infection induced autophagy in 
TABLe 1 | Overview of studies demonstrating the role of mTOR in lymphoid cells following pathogen infection.
Cell type mTOR modification Pathogen Cellular and pathogen outcome Conclusion about mTORs activity 
during infection
Reference
NK cells Rapamycin MCMV Blocked proliferation, IFN-γ synthesis and 
granzyme B expression. Higher viral titer
Promotes proliferation, IFN-γ synthesis and 
granzyme B expression, and pathogen 
clearance
(33)
mTOR−/− NK cells MCMV Blocked proliferation and granzyme B 
expression. Higher viral titer
Promotes proliferation and granzyme B 
expression and pathogen clearance
(31)
CD8 effector T cell-specific Tsc2 deletion 
to enhance mTORC1 
activity
Vaccinia-OVA Excessive generation of effector CD8+ T cells, 
unable to differentiate into memory cells. High 
cytolytic activity. Robust IFN-γ and TNF-α
mTORC1 promotes generation of effectors 
and mTORC1 suppression promotes 
memory formation
(57)
T cell-specific Rictor 
deletion to inhibit mTORC2
Vaccinia-OVA Unaltered CD8 differentiation and effector 
function
mTORC2 does not regulate effector cells (57)
T cell-specific Rheb 
deletion to inhibit mTORC1
Vaccinia-OVA Reduced CD8 effector function. Decreased 
IFN-γ, TNF-α, and cytolytic function
mTORC1 enhances CD8 effector function (57)
Rapamycin LCMV and 
Listeria
Impaired CD8 effector function and reduced 
pathogen clearance
mTORC1 promotes effector function and 
pathogen clearance
(59)
Rapamycin Influenza Reduces IRF4 expression, which is required 
for effector CD8 T cell differentiation and 
expansion. Impaired viral clearance and host 
recovery
mTOR regulates IRF4 expression to 
impact during CD8 T cell differentiation to 
promote pathogen clearance
(61)
Rapamycin LCMV and 
LM-OVA
Impaired effector CD8 T cell number and 
function, Reduced IFN-γ, TNF-α, granzyme 
B, and cytolytic activity. Reduced pathogen 
clearance and survival
mTORC1 promotes effector function, 
pathogen clearance, and host survival
(59)
CD8 
memory
Rapamycin, mTOR, and 
Raptor deletion
LCMV Enhanced memory cell quantity, quality, and 
persistence
mTORC1 suppresses memory quality and 
quantity
(67)
In vitro rapamycin treatment 
prior to cell transfer
LCMV-gp 33 
peptide
Enhanced and long-lived memory cell 
formation
mTORC1 suppresses memory formation (69)
In vitro rapamycin treatment 
of WT and TRAF6−/− cells 
prior to cell transfer and 
infection
LM-OVA Restored the ability to develop memory cells 
and increased the recall response in the 
absence of TRAF6
mTOR blocks memory development and 
recall responses
(68)
T cell-specific Tsc2 deletion 
to enhance mTORC1 
activity
LM-OVA Effector cells were unaltered. Differentiation of 
effector cells to memory cells was impaired. 
Recall response was reduced
Excessive mTORC1 activity inhibits 
memory formation and is regulated by 
Tsc1
(70)
Rapamycin LCMV and 
LM-OVA
Enhanced CD8 memory formation mTOR suppress memory formation (59)
Rapamycin Canary 
poxvirus
Long-term, low dose rapamycin blocked 
memory formation. Short-term, high dose 
rapamycin enhanced CD8 memory
Sustained, low level mTOR activity 
supports memory formation
(71)
Rapamycin Vaccinia virus IL-12-dependent increase in memory CD8 
T cells
IL-12 regulates the mTORC1 block in 
formation of memory CD8 T cells
(76)
T cell-specific Rictor 
deletion to inhibit mTORC2
Vaccinia-OVA Enhanced generation of memory CD8 T cells mTORC2 limits memory cell formation (57)
CD8-
resident 
memory
Rapmycin shRNA silenced 
mTOR
Vesicular 
stomatitis virus 
(VSV) and 
VSV-OVA
Rapamycin increased the quantity of memory 
CD8 in the spleen but reduced resident 
memory cells in the intestinal mucosa and 
vaginal mucosa
mTOR enhanced formation of memory 
cells in the intestinal and vaginal mucosa
(84)
CD8 
secondary 
expansion
Rapamycin LCMV, Pichinde 
virus
IL-15-dependent, virus-induced cell cycling of 
memory CD8 cells was blocked
Inflammatory IL-15 activates the 
mTORC1-signaling pathway to support 
preexisting memory cells and enhance 
antiviral protection
(78)
CD8 T cell 
exhaustion
Rapamycin Chronic LCMV Abrogated therapeutic effects of blocking 
PD-1, leading to CD8 T cell exhaustion and 
failure to control chronic infection
During chronic infection persistent 
antigen impairs mTOR activation, allowing 
FOXO1 activity to increase and promote 
differentiation of terminally exhausted CTLs
(79)
Tfh cells shRNA silenced Rictor or 
Raptor
LCMV Raptor silencing favored Tfh development 
over Th1 development. Rictor silencing 
favored Th1 over Tfh development
IL-2-mediated mTORC1 activation 
promotes Th1 over Tfh development. 
mTORC2 activation favors Tfh over TH1 
development
(118)
(Continued)
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Cell type mTOR modification Pathogen Cellular and pathogen outcome Conclusion about mTORs activity 
during infection
Reference
B cells Mice hypomorphic for 
mTOR and B cell-specific 
deletion of mTOR
S. pneumoniae Decreased germinal centers, high-affinity 
antibodies, and SMH/CSR. Higher mortality in 
hypomorphic mTOR mice
mTOR is a critical immunoregulator, 
promoting germinal center formation 
through AID signaling to generate high 
affinity antibodies
(125)
ATP-competitive mTOR 
kinase inhibitor (TOR-KIs)
Salmonella Early (d14) IgM response was unaltered and 
IgG2c decreased. Late (d28) IgM increased 
and Tfh cell% increased with some evidence 
of increased GC B cells
Partial inhibition of mTOR activity increases 
protective IgM responses
(138)
Rapamycin Influenza 
vaccination and 
heterosubtypic 
challenge
Delayed germinal center formation, reduced 
class switching, increased survival. Increased 
viral clearance
mTOR supports antibody class switching 
and affinity maturation, which may impair 
viral clearance to heterosubtypic infection
(137)
TABLe 1 | Continued
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apoptotic cells in the presence of mTORC1 and mTORC2 activ-
ity, indicating that alternate regulatory mechanisms may override 
suppression of autophagy by mTOR (30). The degree to which 
various pathogens support or inhibit mTOR activity is therefore 
a reflection of the extent to which autophagy benefits or hinders 
their own replication, and the degree to which they have evolved 
to counter host immune responses.
mTOR iN NK CeLL ACTivATiON AND 
eFFeCTOR FUNCTiONS
Natural killer cells are a subset of innate lymphoid cells that 
limit infection by intracellular pathogens and promote tumor 
immunosurveillance. The name “natural killer” reflects their 
capacity to kill target cells without prior antigenic stimulation. 
NK cells develop from common lymphoid progenitor cells 
in the bone marrow in a process dependent on proliferation 
and mTOR. Mice with a conditional deletion of mTOR in NK 
cells had a dramatic reduction in NK cell development and 
differentiation due to defects in proliferation (31). Similarly, 
transplant patients treated with rapamycin had reduced NK 
cell numbers (32).
Following development and maturation in the bone marrow, 
NK cells enter the periphery in a metabolically resting, quiescent 
state. In the periphery, exposure to IL-15 or viruses promotes 
NK cell activation, leading to an increase in metabolism, 
cytokine production, and acquisition of cytotoxic effector func-
tions. High IL-15 concentrations are required to activate mTOR 
(31). Complete NK cell activation requires mTOR signaling, 
as rapamycin and NK cell-specific deletion of mTOR blocked 
proliferation and granzyme B expression in response to in vitro 
cytokine stimulation, in vitro polyI:C stimulation, and MCMV 
infection (31, 33, 34). Consequently, inhibition of mTOR and NK 
function resulted in higher viral titers following MCMV infection 
(31, 33). Interestingly, IFN-γ secretion was unimpaired following 
MCMV infection in mice with a NK cell-specific mTOR dele-
tion, yet it was blocked in MCMV-infected mice treated with 
rapamycin (33). This difference could be due to the fact that rapa-
mycin inhibits mTOR in cells other than NK cells, suggesting that 
mTOR signaling in other cell types may impact NK cell effector 
functions. Alternatively, rapamycin may inhibit the mTOR path-
way to a different extent than genetic deletion of mTOR in NK 
cells.
mTOR complex 1 regulates NK cell effector function by 
enhancing glucose uptake and promoting aerobic glycolysis. 
Accordingly, directly limiting glycolysis inhibits IFN-γ produc-
tion and granzyme B expression by NK cells (35). Cells infected 
with pathogens typically increase glucose uptake and glycolysis 
and therefore, limit the amount of glucose available to surround-
ing immune cells (36). The effector functions of NK cells may 
therefore be hindered by the availability of glucose following 
infection. During the initial phase of MCMV infection, prolifera-
tion of NK cells is IL-15 and mTOR dependent. However, NK cell 
proliferation subsequently becomes IL-15 and mTOR independ-
ent, at which point proliferation is driven by activating receptors 
on the NK cell, such as Ly49H, which recognizes viral ligands 
on infected cells, but does not activate mTOR (37, 38). The later, 
mTOR-independent phase of such immune responses may be an 
adaptation to maintain NK effector functions with diminishing 
glucose supplies. Regardless, this model illustrates that immune 
response kinetics influence the requirement for mTOR signaling 
in pathogen defense.
mTOR iN iNKT CeLL DeveLOPMeNT, 
ACTivATiON, AND eFFeCTOR 
FUNCTiONS
Signaling through mTOR is also important in the development, 
activation, and effector function of invariant NKT cells (iNKT) 
cells. iNKT cells share features common with both NK cells and 
T cells. Similar to NK cells, iNKT cells rapidly produce large 
amounts of cytokines following activation, including IFN-γ, 
TNF-α, IL-4, and IL-17. However, unlike NK cells, iNKT cells 
express a T cell receptor (TCR) similar to conventional T cells, 
albeit at intermediate levels and with decreased diversity. In mice, 
the iNKT TCR consists of a Vα14Jα18 α-chain paired with Vβ2, 
Vβ7, or Vβ8.2 β chains. The iNKT cell TCR recognizes lipid 
antigens bound to the non-classical major histocompatibility 
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complex (MHC) homolog, CD1d. These cells contribute to tumor 
immunity, autoimmunity, and immunity to pathogens.
Invariant natural killer T cells can be divided into subsets based 
on transcription factor expression and cytokine production. 
Expression of the transcription factors T-bet, GATA3, and RORγt 
define the NKT1, NKT2, and NKT17 subsets, respectively (39, 
40). Mice with a conditional deletion of Raptor in T cells showed 
that mTORC1 is required for the development of the NKT1 
subset, and to a lesser degree, NKT2 cells (41, 42). Furthermore, 
the remaining iNKT cells were functionally compromised, as they 
failed to produce IFN-γ and TNF-α following stimulation with 
α-Gal-Cer. These data indicate that mTORC1 is differentially 
required for NKT cell development and effector functions.
While mTORC1 was required for development of NKT1 
and NKT2 cells, mice with abrogated mTORC2 signaling had 
a defect in NKT17 development (43). Moreover, development 
of NKT17 cells was enhanced in a Rictor-dependent manner 
in the absence of PTEN, further clarifying that differentiation 
of the NKT17 lineage is mTORC2 dependent, but mTORC1 
independent. However, Prevot et  al. found that mTORC2 was 
required for the development of NKT2, but not NKT1 or NKT17 
cells (44). The reason for this inconsistency is not known as 
both studies used mice with a conditional deletion of Rictor 
in T cells for their studies. Possible factors that contribute to 
such variable findings include diverse microbiomes associated 
with the different facilities, use of different markers to identify 
iNKT cell subsets, and technical difficulties associated with the 
reagents available to analyze iNKT cell transcription factors. 
An intriguing study recently showed that in the presence of 
IL-10 and rapamycin, iNKT cells expressed Foxp3 and acquired 
properties associated with immunosuppressive regulatory cells, 
identifying yet another population of iNKT cells: Foxp3+ iNKT 
cells (iNKTregs) (45).
Stimulation of iNKT cells with α-Gal-Cer activates mTOR 
signaling (46). Mice with an inducible deletion of Raptor in 
mature iNKT cells showed that mTORC1 signaling is required 
for optimal proliferation and IL-4, IFN-γ, and TNF-α synthesis 
following in vitro and in vivo stimulation with α-Gal-Cer (42). 
Moreover, Raptor deficiency inhibited iNKT-mediated autoim-
mune hepatitis, which arises in part, due to TNF-α produced by 
iNKT cells, further highlighting a role for mTOR in regulating 
iNKT cell effector function.
A role for iNKT cells in pathogen defense is clearly evident 
following their activation with artificial ligands during infection 
with different pathogens including malaria (47), HIV (48), influ-
enza virus (49), and hepatitis B virus associated hepatic carcinoma 
(50). In addition, iNKT cells mediate pathogen defense against 
several strains of bacteria that express microbial glycolipids and 
diacylglycerols capable of binding CD1d molecules, such as 
Streptococcus pneumoniae (51, 52), Novosphingobium aromati-
civorans (53), and Borrelia burgdorferi (52). At present, mTOR 
has not been implicated in pathogen responses mediated by iNKT 
cells. However, as mTOR is required for the development and 
function of iNKT cells, it is perhaps only a matter of time before 
a role for mTOR in regulating pathogen defense by iNKT cells is 
established.
mTOR iN CD8 T CeLL iMMUNiTY TO 
PATHOGeNS
CD8+ T cells play a pivotal role in host defense against pathogens 
by directly killing infected cells via release of cytotoxic granules 
containing granzymes and perforin, and indirectly through 
cytokine secretion. A critical role for mTOR is implicated in 
several stages of CD8 T cell-mediated immunity including activa-
tion, differentiation, migration, and memory formation.
Naive CD8+ T cells undergo sequential stages of activation, 
clonal expansion, and differentiation to generate pathogen-
specific effector CD8+ T cells. Activation of naive CD8+ T cells 
requires recognition of their cognate antigen presented by MHC 
class I molecules on the surface of antigen-presenting cells 
(APC). Engagement of the TCR with antigen and MHC, in the 
context of costimulation, induces PI3K signaling and subsequent 
activation of mTORC1 via TSC1-dependent and -independent 
processes. Activation of mTORC1 independent of TSC1 occurs 
through binding of the chaperone protein, Hsp90 to Raptor. The 
interaction of Hsp90 and Raptor promotes mTORC1 activation 
and prevents T cell anergy, as activation of T cells during a block-
age of Hsp90 led to T cell tolerance (54).
One way in which mTOR regulates T cell activation is by 
blocking negative regulators of T cell activation. In particular, 
naive CD8+ T cells are kept in a state of quiescence by several 
transcription factors including KLF4 and E74-like factor 4 
(ELF4). Signaling through mTOR inhibits KLF4 and ELF4 and 
reverses quiescence following TCR engagement, allowing CD8+ 
T cell activation and proliferation to proceed (55).
Following CD8+ T cell activation, antigen-specific T cells 
undergo clonal expansion and differentiate into effector cells. 
Progression to effector CD8+ T cells is coordinated with a 
switch from catabolism to anabolism and oxidative glycolysis. 
CD8+ T cells drastically increase their glucose metabolism as 
they respond to pathogens and differentiate into effectors (56). 
Signaling through mTORC1 promotes glycolysis in effector 
CD8+ T cells, and mTOR inhibition with rapamycin suppresses 
this process. Indeed, CD8+ T cells deficient in mTORC1 signaling 
failed to develop into effector cells following Vaccinia infection 
(57, 58). Likewise, rapamycin treatment during crucial stages of 
infection impaired glycolysis and impeded CD8+ effector func-
tion and pathogen clearance during infection with lymphocytic 
choriomeningitis virus (LCMV) and L. monocytogenes (59). 
Conversely, genetic deletion of Tsc2 and enhanced mTORC1 activ-
ity led to excessive generation of CD8+ effector cells. Importantly, 
constitutively activate mTORC1 produced terminally differenti-
ated effector cells and impaired memory development (57). 
While mTORC1 activity is required to generate effective CD8+ 
effector cells, mTORC2 appears to be dispensable as mice with 
a conditional deletion of Rictor exhibit normal proliferation and 
effector functions (57).
Effector differentiation of CD8+ T cells is tightly regulated by 
several transcription factors. The transcription factor HIF-1α is 
required to sustain glucose metabolism and expression of perforin 
and granzymes in effector CD8+ T cells (58). HIF-1α controls 
glycolysis by regulating expression of the glucose transporter, 
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Glut1. As CD8+ T cells differentiate into effectors, they increase 
expression of HIF-1α in an mTORC1- and IL-2-dependent man-
ner. Therefore, inhibition of mTORC1 with rapamycin inhibits 
HIF-1α and Glut1 expression, glucose uptake, and glycolysis (58). 
Signaling through mTOR also promotes glycolysis via the onco-
gene c-MYC, which regulates metabolic reprograming in T cells 
following activation (60). Expression of c-MYC is upregulated 
in an mTOR-dependent manner following TCR stimulation and 
influences the expression of rate-limiting glycolytic enzymes (60).
Although the HIF-1α complex is required to sustain glycolytic 
metabolism in CD8+ T cells, it is not required to initiate the 
process nor is it essential for T cell proliferation (58). In contrast, 
the transcription factor interferon regulatory factor 4 (IRF4) was 
critical for proliferation and survival of CD8+ T cells respond-
ing to infection with influenza virus and L. monocytogenes (61, 
62). IRF4 maintains aerobic glycolysis and effector functions in 
activated CD8+ T cells by promoting the expression of multiple 
glycolytic enzymes (62). IRF4 expression in CD8+ T cells is 
regulated by mTOR, and is proportional to the strength of TCR 
stimulation, such that strong TCR stimulation increases mTOR 
activity, which enhances IRF4 expression and CD8+ T cell 
expansion and effector differentiation. Conversely, rapamycin 
treatment reduced mTOR signaling and impaired IRF4 expres-
sion and CD8+ T  cell differentiation, leading to impaired viral 
clearance and host recovery from infection (61).
SEMA4A is a class IV semaphorin that activates mTORC1 
signaling and is also required for optimal CD8+ T cell activation 
and differentiation (63). SEMA4A-mediated mTOR signaling was 
not important in the early phases of CD8+ T cell activation, but was 
important for acquisition of effector functions. Interestingly, IRF4 
expression was unaltered in SEM4A4-deficient mice, yet effector 
differentiation was impaired, indicating that IRF4-dependent 
signaling may be necessary, but not sufficient, for differentiation 
of CD8+ effector T cells. Furthermore, the SEMA4A-plexin B2 
axis shifts mTOR-mediated signaling from mTORC2 to mTORC1 
in CD8+ T cells (63).
After expansion in the lymph nodes, effector CD8+ T cells 
travel to the site of infection to kill infected cells. Migration 
from the lymph node to the site of infection is in part, due to 
downregulation of CD62L and CCR7, which is dependent on 
activated mTOR (64). Such regulation by mTOR is evident from 
maintenance of CD62L and CCR7 in cells treated with rapamy-
cin, leading to the accumulation of these cells in the secondary 
lymphoid organs rather than non-lymphoid tissue (65).
Following the dramatic CD8+ T cell expansion, and subsequent 
clearance of the pathogen, T cells go through a contraction phase 
leaving a resolute population of memory cells. The transition 
from effector to memory cells is coordinated with a transition 
from high mTOR activity to low mTOR activity. In contrast to 
CD8+ effector T cells, which favor glucose over fatty acid metabo-
lism for energy, memory cells are less glycolytic and rely on lipid 
metabolism to break down fatty acids, amino acids, and glucose 
interchangeably (66).
The role of mTOR in regulating the transition from effec-
tor to memory cells has been studied extensively. Treatment 
of mice with a low dose of rapamycin or genetic depletion of 
Raptor-enhanced memory CD8+ T cell formation by promoting 
the generation of memory precursor cells, indicating that high 
mTOR signaling suppresses memory CD8+ T cell differentiation 
(67, 68). Similarly, adoptive transfer of LCMV-specific T cells 
cultured with rapamycin showed an increase in oxidative phos-
phorylation and were long-lived, compared to non-treated cells 
(69). Conversely, increasing mTOR via Tsc1 deletion in T cells led 
to a decrease in memory T cells following L. monocytogenes infec-
tion, suggesting that TSC1 promotes memory CD8+ T cell forma-
tion by regulating mTOR activity (70). While reducing mTOR 
signaling increases memory T cells, it comes at the expense of an 
optimal primary effector response, which occurs due to impaired 
glycolysis in the CD8+ T cells after activation (59).
Although a low dose of rapamycin can augment memory 
formation in response to certain pathogens, long-term blockage 
of mTORC1 with the same low dose of rapamycin abrogated for-
mation of memory CD8+ T cells in response to canary poxvirus 
vaccination (71). In this study, a short duration of a high dose 
of rapamycin during the expansion phase enhanced memory 
CD8+ T cell responses. Several factors could contribute to these 
observed differences in generating memory cells with rapamycin, 
including the strength of TCR stimulation, the level of mTOR 
activity induced with each pathogen, differential requirements 
and timing of pathogen replication, and experimental differences 
in the location (blood versus lymph node and spleen) where the 
T cells were analyzed. A recent study indicated that signaling 
through IFN-γR, with low, but not high TCR signaling, promoted 
mTOR signaling and generation of short lived effector cells, 
while simultaneously blocking the formation of memory precur-
sors (72). Given that TCR signaling differs between pathogens, 
pathogen dose, and even between epitopes of the same pathogen 
(73), it is not surprising that rapamycin has varied impacts on the 
CD8 response to different pathogens. In addition, Rictor-deficient 
mice showed enhanced generation of memory CD8+ T cells, 
which implicates mTORC2 in suppressing memory cell forma-
tion (57). As mTORC2 does not impact formation of effector 
cells, yet suppresses memory formation, inhibition of mTORC2, 
rather than mTORC1, may provide an alternate means to boost 
CD8 memory T cells.
Studies investigating CD8-mediated tumor immunity demon-
strate that mTOR controls memory CD8+ T cell differentiation by 
regulating two transcription factors, T-bet and Eomesodermin 
(Eomes) (74, 75). In vitro inhibition of mTOR with a low dose 
of rapamycin reduced T-bet expression and enhanced Eomes 
expression in CD8+ T cells, leading to augmented memory 
responses following adoptive transfer in vivo (74). A recent study 
indicates that mTOR also controls vaccinia virus-specific CD8+ 
T cell differentiation by regulating T-bet (76). Therefore, it is 
likely that mTOR similarly regulates memory differentiation in 
response to pathogens through T-bet and Eomes.
The effector to memory cell transition is also coupled with 
the cytokine environment, which appears to be critical for 
optimal memory development (77). Activation of mTOR by 
IL-7 promotes T-bet expression and upregulates IL-2Rβ. This, in 
turn, allows IL-15, which also utilizes IL-2Rβ for signaling, to 
promote differentiation of effector cells to memory cells through 
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the upregulation of Eomes (75). IL-15 appears to be particularly 
important in promoting optimal memory following LCMV infec-
tion by transiently inducing cell-cycle progression, independent 
of antigen re-encounter, via a mTORC1-dependent pathway. This 
induces more rapid cell division and more protective memory 
cells following encounter with viral antigen (78). Thus, mTOR 
signaling impacts multiple stages of T cell activation and memory 
formation, and the impact of mTOR signaling can have different 
outcomes based on the stage of cellular differentiation.
An additional role for mTOR in regulating T cell exhaustion 
in response to chronic infection has emerged (79). T cell exhaus-
tion refers to a state of dysfunction marked by reduced effector 
functions due to the persistence of antigen and inflammation 
(80). Following chronic LCMV infection, Akt and mTOR sign-
aling were impaired in CD8+ effector T cells. This reduction in 
mTOR activity led to increased activity of the transcription factor, 
FOXO1 and subsequent upregulation of the inhibitory receptor, 
programed cell death protein 1 (PD-1), which promotes CD8+ 
T cell exhaustion (79). Blockade of PD-1 increased mTOR activity 
and decreased CD8+ T cell exhaustion. Furthermore, suppression 
of the mTOR pathway abrogated the therapeutic effects of PD-1 
blockade, suggesting that mTOR activity is required to reverse 
T cell exhaustion by PD-1 blockade.
Recently, a population of long-lived, resident memory CD8+ 
T cells (TRM) that resides in peripheral tissues has been defined. 
TRM cells are non-recirculating memory T cells located at barrier 
sites, including the skin and mucosal tissue (81, 82). Reactivation 
of TRM stimulates innate immunity against antigenically unrelated 
pathogens, and could potentially enhance vaccine efficacy (83). 
While rapamycin promotes memory development in lymphoid 
tissues, it blocks formation of TRM cells (84). Specifically, rapa-
mycin treatment blocked formation of Vesicular stomatitis virus 
(VSV)-specific TRM cells in the intestine and vaginal mucosa; 
however, lung TRM cells were unaltered (84). Thus, mTOR appears 
to promote formation of mucosal resident memory cells in spe-
cific tissues following VSV infection. As such, promoting mTOR 
activation rather than inhibiting it may prove more beneficial in 
enhancing formation of TRM cells.
In summary, signaling mediated by mTOR has diverse roles 
in CD8+ T cell-mediated immunity to pathogens including 
activation of naive precursors, migration of pathogen-specific 
cells, development of effector functions, regulation of chronically 
stimulated effector cells, and generation of stable memory cell 
populations. Each of these stages poses a potential for immune 
intervention. However, with such diverse roles, therapeutic regu-
lation of the mTOR pathway will require extensive analysis of the 
potential implications.
mTOR iN CD4 T CeLL DiFFeReNTiATiON 
AND iMMUNiTY TO PATHOGeNS
CD4+ T cells play both supportive and direct roles in host 
defense against pathogens. As helper cells they regulate the 
responses of innate immune cells, cytotoxic CD8+ T cells, and 
 antibody-forming B cells. In particular, CD4 T cells are absolutely 
required for generating long-lived, protective antibodies. As direct 
effectors, CD4 T cells can utilize perforin-dependent cytolysis of 
infected cells (85, 86). Similar to CD8+ T cells, naive CD4+ T cells 
are initially primed in secondary lymphoid organs following 
binding of their TCR to microbial peptides presented by APCs. 
CD4+ TCR engagement, coupled with co-stimulation, leads to 
PI3K signaling, mTOR activation, and subsequent development 
into effector and memory populations (87).
Following antigen encounter, naive CD4+ T cells can dif-
ferentiate into several distinct subsets including T helper cells 
(Th1, Th2, and Th17), T follicular helper cells (Tfh), effector 
cells, and regulatory T cells (Treg). Each CD4+ T cell lineage is 
associated with the expression of specific transcription factors: 
T-bet (Th1), Gata-3 (Th2), RORγt (Th17) Foxp3 (Treg), and Bcl-6 
(Tfh) (88). mTOR is a key regulator of differentiation of CD4+ 
T cells. Specifically, differentiation into Th1, Th2, and Th17 cell 
lineages was severely inhibited in mTOR-deficient mice, even in 
the presence of polarizing cytokines (87, 89). In the absence of 
mTOR signaling, impaired phosphorylation of STATs in response 
to cytokine stimuli blocked the induction of the lineage specific 
transcription factors (89, 90). Conversely, suppression of mTOR 
with rapamycin or genetic deletion of mTOR in T cells promoted 
differentiation to FoxP3+ Treg cells, indicating that mTOR 
 signaling blocks Treg development (89).
Subsequent studies using conditional deletion of Raptor, Rheb, 
or Rictor in T cells ascertained the contribution of mTORC1 and 
mTORC2 in T helper differentiation. Deficiency of Rheb, which 
is an activator of mTORC1 signaling, impaired differentiation of 
Th1 and Th17 cell lineages (91). However, Raptor-deficient T cells 
showed a defect in Th17, but not Th1 differentiation (92). More 
recently, it was shown that Th2 differentiation was also drasti-
cally compromised in the absence of Raptor (93). On the other 
hand, deficiency of Rictor and mTORC2 signaling impaired Th2 
differentiation, but not Th1 or Th17 (91). However, a conflict-
ing study suggested that mTORC2 signaling was also required 
for Th1 and Th2 differentiation (94). Furthermore, the loss 
of Th2 differentiation observed in Rictor-deficient T cells was 
comparatively minor compared to the loss observed following 
rapamycin treatment of Rictor-deficient T cells, indicating a 
more prominent role for mTORC1 in Th2 differentiation (93). 
Thus, it is clear that both mTORC1 and mTORC2 complexes 
play important roles in Th differentiation; however, the pre-
cise roles of each pathway in each of the subsets remain to be 
resolved.
Similar to CD8+ T cells, differentiation of naive CD4+ T cells to 
Th1, Th2, and Th17 effector cells represents a shift from oxidative 
phosphorylation to glycolysis. Th1, Th2, and Th17 cells express 
high levels of Glut1 and are highly glycolytic via mTOR signaling, 
which sustains their high energy consumption and supports their 
diverse effector functions (95). Development and maintenance of 
Th17 cells, in particular, is heavily reliant on glycolysis, which is 
stimulated by HIF-1α downstream of mTOR (96, 97). Therefore, 
signaling through mTOR contributes to resistance to a variety 
of pathogens via regulating transcription factors essential for 
developing T-helper subsets, and by maintaining glycolysis of 
these subsets following activation.
9Keating and McGargill mTOR in Immunity to Pathogens
Frontiers in Immunology | www.frontiersin.org May 2016 | Volume 7 | Article 180
mTOR iN Treg CeLL-MeDiATeD 
iMMUNiTY TO iNFeCTiON
Regulatory T cells contribute most significantly to pathogen 
defense by suppressing T cell responses to limit immunopathol-
ogy following infection (98). Foxp3+ expression distinguishes 
Treg cells from conventional T cells and confers Treg cell func-
tion (99, 100). Inhibition of mTOR signaling through either 
genetic deficiency or rapamycin treatment promoted expansion 
of preexisting Treg cells (89, 101–103) and induced the Treg cell 
phenotype on conventional T cells and Th17 cells (96, 104–106). 
Thus, mTOR is critical for negatively regulating Foxp3 expression 
and Treg cell numbers.
The stability and function of Treg cells is influenced by inflam-
mation. In particular, Foxp3 Treg cells can be reprogramed into 
Th1 and Th17 effectors in the gut or sites of parasitic infection. 
However, reprograming of Treg cells into Th1/Th17 effectors 
is blocked with rapamycin, which stabilizes Foxp3 expression 
in vivo (107). Thus, mTOR signaling promotes differentiation of 
Treg cells into T helper cells when needed. Indeed, both Th17 
and Treg cells require TGF-β for their differentiation, and the 
degree of mTOR activation delineates the relative development 
of each cell type. High levels of mTOR activation promote Th17 
cell differentiation (108), whereas low mTOR signaling promotes 
Treg accumulation and sensitizes Treg cells to TGF-β (87, 109).
Furthermore, mTOR orchestrates a metabolic checkpoint for 
the differentiation between Treg cells and Th17 cells. Conditions 
that induced Th17 differentiation led to an induction of HIF-
1α, which was dependent on mTOR signaling (96). HIF-1α, in 
turn, increased the expression of glycolytic enzymes and Th17 
development, while simultaneously dampening Treg cell devel-
opment. Thus, blocking glycolysis and mTOR promotes Treg 
cell generation by downregulation of HIF-1α (96). Similarly, the 
ratio between Th1 and Treg cells is also regulated by sphingosine 
1-phosphate (S1P), which signals through mTOR and attenuates 
activity of SMAD3 to antagonize TGF-β, and inhibit generation 
of Treg cells and promote Th1 development (110).
In general, mTOR signaling suppresses Treg cell differentiation 
in favor of T helper differentiation, which increases immunity to 
pathogens by supporting the antimicrobial effector functions of 
T helper cells. Inhibition of mTOR can support development of 
Treg cells to restrain and control immune responses to circumvent 
excessive immunopathology. However, Raptor deficiency specifi-
cally in Treg cells unexpectedly impaired the suppressive function 
of Tregs and resulted in a fatal inflammatory disease, suggesting 
that the mTORC1 complex is also important to maintain Treg 
homeostasis and function (111). These seemingly contradictory 
data again highlight the complexity of the mTOR complexes, and 
the need to further delineate this signaling pathway.
mTOR iN Tfh CeLL iMMUNiTY TO 
PATHOGeNS
Tfh cells are a subset of differentiated CD4+ T cells with a crucial 
role in initiating and maintaining germinal center reactions and 
high affinity isotype-class-switched antibody responses (112). 
Tfh cells express the transcription factor, Bcl6, which defines 
Tfh cells and promotes expression of the chemokine receptor, 
CXCR5 (113–115). In contrast to differentiation of Th1, Th2, and 
Th17 cells, which is supported by IL-2-mediated activation of 
mTOR, differentiation of Tfh cells is suppressed by IL-2 activa-
tion of mTOR. Th1 differentiation requires STAT5 activation 
and subsequent Blimp-1 expression, whereas Tfh cells develop 
when Blimp-1 synthesis is suppressed, enabling Bcl6 expression 
(116,  117). Indeed, Blimp-1 and Bcl6 expression are mutually 
exclusive, and over expression of either drives differentiation of 
Th1 or Tfh cells, respectively (113). During acute LCMV infection, 
Akt and mTOR signaling were essential for Blimp-1 and T-bet 
expression, which induced Th1 differentiation and countered Tfh 
development (118). Silencing of Rictor or Raptor demonstrated 
that mTORC1 suppresses Tfh cell development and induces Th1 
cells, while mTORC2 may suppress Th1 cell development to per-
mit preferential differentiation of Tfh cells in response to LCMV 
infection (118). Thus, commitment to either Th1 or Tfh lineages 
is discerned by the level of IL-2–STAT5–mTOR signaling, with 
increased signaling correlating with the Th1 transcription factors, 
T-bet and Blimp1, and lower IL-2–STAT5–mTOR levels with the 
Tfh transcription factor, Bcl6 (115, 116, 119–121).
A recent study demonstrated that during influenza virus 
 infection, TGF-β opposes IL-2 to produce more Tfh cells and 
isotype-switched antibody responses rather than Th1 cells (122). 
TGF-β suppressed mTOR activation in T cells early during infec-
tion, which promoted Tfh cell differentiation by limiting IL-2 
signaling. Inhibition of mTOR with rapamycin also promoted Tfh 
cell differentiation, suggesting that TGF-β restricts IL-2 respon-
siveness and insulates early Tfh progenitor cells from mTOR 
signaling to promote Tfh cell differentiation and isotype-switched 
antibody responses (122).
Bcl6 expression in Tfh cells downregulates genes associated 
with glycolysis, while T-bet in Th1 cells inhibits Bcl6-mediated 
repression of these genes to promote glycolysis (123). Accordingly, 
Tfh cells are less proliferative, and less glycolytic than Th1 cells, 
due to a lack of IL-2 signaling and a lower level of mTOR activa-
tion. Tfh cells therefore have a reduced metabolic capacity, similar 
to Treg cells, and also utilize oxidative phosphorylation for cel-
lular maintenance (118).
Similar to the reciprocal relationship between Th17 and Treg 
cell activation, mTOR activation also plays a key role in regulat-
ing the balance between Th1 versus Tfh responses. While both 
Treg and Tfh cells are suppressed by mTOR activity and share 
metabolic similarities, Treg cells typically suppress and control 
immune responses, whereas Tfh cells typically promote immune 
responses, primarily germinal center formation and high affinity 
antibody responses.
mTOR iN B CeLL-MeDiATeD iMMUNiTY 
TO PATHOGeNS
B cells are responsible for producing pathogen-specific antibodies 
that block infection and control pathogen spread. Once gener-
ated, antibodies persist to provide long-lasting immunity. B cells 
develop in the bone marrow through several stages of maturation 
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and differentiation that are influenced by mTOR signaling. Mice 
with a hypomorphic allele of mTOR have a partial block in B cell 
development in the bone marrow, and altered proportions of B 
cell subsets in the spleen (124). Conditional deletion of mTOR 
in B cells via CD19-cre did not abrogate development, but 
decreased mature, T2 transitional, and marginal zone B cells in 
the spleen (125). In addition, B cells lacking components of the 
mTORC2 complex had altered development. B cells deficient in 
Sin1 accumulated at the pro-B cell stage in the bone marrow, and 
had a reduced capacity to become IgM+ immature B cells due to 
decreased Akt activation (126). Conditional deletion of Rictor, 
mediated by Vav-cre, did not perturb B cell development in the 
bone marrow, but did reduce mature B cells in the spleen (127). 
Interestingly, conditional deletion of Tsc1 in B cells, which renders 
mTOR constitutively active, also impaired B cell maturation and 
significantly reduced marginal zone B cells (128, 129). Together, 
these studies show that both a reduction in mTOR activity and 
constitutive activation of mTOR can negatively impact B cell 
development, suggesting that the level of mTOR activation in 
B cells is critical for optimal B cell development.
Following development in the bone marrow, B cells migrate to 
secondary lymphoid organs and mature into follicular or marginal 
zone B cells, and remain quiescent until stimulated. B cells exhibit 
basal levels of mTOR activity in response to nutrients without 
stimulation. mTOR activity levels vary across B cell types, with 
marginal zone B cells maintaining high levels of mTOR activity, 
and follicular B cells having lower levels of mTOR activity (130). 
Activation through the BCR, TLR, or CD40 induces mTOR sign-
aling (131). Similar to T cells, initial B cell activation increases 
glucose uptake and glycolysis to promote clonal expansion, which 
is also dependent on the mTOR pathway. Rapamycin inhibited 
B cell proliferation in response to anti-CD40, LPS, BAFF, and 
the polyclonal activator, S. aureus (131–136). In addition, B cells 
expressing the hypomorphic allele of mTOR had decreased 
proliferation in response to anti-IgM, anti-CD40, and LPS, with 
a bigger reduction following anti-IgM and anti-CD40 than LPS 
(124). These data demonstrate that mTOR signaling is essential 
for B cell proliferation in response to multiple stimuli.
Upon activation, B cells can either differentiate rapidly into 
plasmablasts that secrete low affinity IgM antibodies, or form 
germinal centers within secondary lymphoid organs, which are 
important for the generation of memory B cells and high affinity, 
isotype-class-switched antibody responses. As described above, 
the formation of germinal centers is dependent on interac-
tion with Tfh cells. In the germinal centers, B cells proliferate 
and undergo somatic hypermutation (SHM) and class switch 
recombination (CSR). SHM increases antibody diversity by 
introducing point mutations into heavy chain Ig genes. CSR 
increases diversity further by rearranging the Ig heavy chain 
genes to express a constant region of a specific Ig antibody class. 
Initiation of these processes relies on activation-induced cytidine 
deaminase (Aicda; AID), which creates mutations in DNA by 
deaminating cytidine residues to generate uracil, leading to base 
pair mis-matching. Mutated B cells then undergo affinity-driven 
selection in the germinal centers, which is necessary for the gen-
eration of high affinity antibodies and optimal protection against 
pathogens.
Mechanistic target of rapamycin signaling is critical for the 
formation of germinal centers and the production of high affin-
ity antibodies. Mice with a hypomorphic allele of mTOR had 
decreased antibody responses to T-independent and T-dependent 
antigens, with a more pronounced decrease in IgG compared to 
IgM antibodies (124). Further analysis of mice with the hypomor-
phic mTOR allele following immunization with either the model 
antigen NP-CGG, or heat-killed Pn14 derived from S. pneumo-
niae showed decreased germinal center formation, SHM, CSR, 
and IgG antibody affinity maturation (125). Challenge of mice 
with the hypomorphic mTOR allele with live S. pneumoniae led to 
reduced antibody titers and survival, compared to wild-type mice 
(125). Likewise, mice with a B cell-specific deletion of mTOR also 
had reduced germinal center formation and high affinity antibody 
generation following immunization with NP-CGG (125). In both 
cases, decreased mTOR signaling caused a reduction in the RNA 
and protein levels of AID. Rescue experiments, increasing AID 
levels in B cells with low mTOR activity, restored CSR, indicating 
that mTOR regulates the generation of high affinity antibodies 
through AID signaling (125).
Consistent with these findings, treatment of mice with a low 
dose of rapamycin during influenza vaccination blocked ger-
minal center formation, Aicda transcription, and consequently, 
CSR (137). Furthermore, AID induction was dependent on 
signaling via mTORC1, as Aicda transcription was not induced 
in Raptor-deficient B cells following stimulation. In addition, 
mTOR was critical for CSR independent of proliferation, as the 
dose of rapamycin used in these experiments was low enough 
to support proliferation, yet Aicda transcription and CSR were 
inhibited (137).
Given that high affinity, class-switched antibodies are required 
for optimal protection against most pathogens, it was surprising 
that treatment of mice with a low dose of rapamycin during 
influenza vaccination improved protection against subsequent 
infections with different influenza subtypes (137). Analysis of the 
rapamycin-treated mice revealed a block in germinal center for-
mation and CSR, which generated a broader antibody response, 
rather than a highly selected and affinity-matured repertoire. The 
majority of antibodies generated during influenza vaccination are 
high affinity antibodies specific for the globular head of the influ-
enza hemagglutinin (HA) molecule. However, the HA protein is 
also the most variable protein between different influenza strains. 
Therefore, highly specific antibodies that protect against one 
subtype of influenza often do not protect against other subtypes. 
By blocking germinal center formation, rapamycin hampered 
the generation of high affinity antibodies specific for the variable 
region, with the unexpected benefit of allowing the lower affinity 
antibodies that are specific for conserved portions of influenza to 
become more prevalent. These data suggest that altering the levels 
of mTOR activation can steer the immune response away from 
strain-specific responses to more cross-reactive responses, which 
would be beneficial in generating a universal influenza vaccine.
It was also reported that mice with a conditional deletion of 
Tsc1 in B cells, which renders mTOR constitutively active, also 
had a defect in germinal center formation, and a reduction in 
T-dependent and T-independent antibody production (128). 
These data suggest that the level of mTOR activation in B cells is 
FiGURe 2 | mTOR activity differs across cell subsets. Recognition of microbial components via TLRs leads to activation and subsequent migration of DC from 
the site of infection to the draining lymph nodes. Activated DCs upregulate costimulatory molecules to become highly efficient antigen-presenting cells. TCR 
recognition of microbial antigens presented by DC leads to activation and differentiation of CD4+ T cells, CD8+ T cells, and iNKT cells. This TCR-mediated activation 
is coupled with activation of mTOR and acquisition of effector functions. High mTOR activity is typically associated with high glycolytic and metabolic activity, 
whereas low mTOR activity is typically associated with low glycolytic activity and a more quiescent state. Activation of naive CD4+ T cells leads to an increase in 
mTOR activity and expression of transcription factors that promote the differentiation of Th1, Th2, and Th17 cells. Conversely, differentiation of CD4+ T cells in the 
absence of mTOR signaling promotes development of Treg cells and Tfh cells. Treg cell differentiation is supported by IL-2 and Tfh cell differentiation is suppressed 
by IL-2. Mature Tfh cells initiate germinal center reactions and support generation of high affinity isotype-class-switched antibody responses. High mTOR activity 
also supports the generation of CD8 effectors cells, whereas a dampening of mTOR activity supports the transition to memory CD8+ T cells. Cells are depicted in 
their activated state, unless specified as naive or memory.
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critical for optimal germinal center formation. However, another 
group found that mice with a conditional deletion of Tsc1 in B 
cells did not have defects in germinal center formation or high 
affinity antibody production (129). The reason for the discrep-
ancy in these reports is not clear as both groups observed the 
same defects in B cell development in the absence of Tsc1.
Assessing the role of mTORC2 in antibody generation has 
also yielded seemingly conflicting data. In one study, inactiva-
tion of mTORC2, via Rictor deletion, impaired germinal center 
differentiation and antibody responses, demonstrating that 
mTORC2 supports antibody differentiation (127). However, in 
a subsequent study, partial mTORC2 inhibition through incom-
plete Rictor deletion increased CSR compared to wild-type mice, 
illustrating negative regulation of antibody responses by mTORC2 
(138). Different levels of Rictor depletion or targeting B cells at 
different stages of development may have contributed to these 
discrepancies. The first study reported efficient deletion of Rictor 
in all hematopietic cells using Vav-cre, or a tamoxifen-inducible 
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Cre (127). Whereas Limon and colleagues obtained partial Rictor 
depletion with CD19-cre (138). In addition, Limon et  al. used 
varying doses of a new class of ATP-competitive mTOR kinase 
inhibitors to show that partial mTORC2 deletion enhances 
CSR. Partial deletion of mTORC1 or complete deletion of both 
mTORC1 and mTORC2 resulted in decreased, rather than 
increased CSR. However, partial inhibition of both mTOR 
complexes with inhibitors, or partial deletion of Rictor enhanced 
CSR. The increase in CSR was dependent on FOXO transcription 
factors (138). These data again highlight that the level of mTOR 
activation is a critical determinant on the cellular response.
Tfh cells and B cells act in unison to promote germinal center 
formation, CSR, and high affinity antibody responses. Yet, 
mTORC1 signaling typically suppresses Tfh cell development and 
function, while promoting CSR in B cells. While such a scenario 
does not create a quandary for cell-specific mTOR signaling, 
inhibition of the mTOR in the whole organism through either 
deletion of mTOR or with rapamycin treatment is likely to 
have opposing affects on antibody formation via Tfh cells and 
B cells. Similar to the self-regulating mechanism influencing 
differentiation of Treg cells versus Th1 cells or Tfh versus Th17 
cells, the balance between B cell and Tfh cell function may be 
regulated by as yet unknown mechanisms. Initial inhibition of 
mTOR could allow development and function of Tfh cells to 
promote germinal center formation, followed by a period of 
enhanced mTOR activity to allow B cell proliferation and CSR to 
proceed.
CONCLUSiON
It is now clear that mTOR has a central role in coordinating 
the outcome of pathogen defense by modulating immunity 
mediated by lymphoid cells. However, many details of the 
host–pathogen interaction, and their implications, are still to 
be determined. The mTOR-signaling pathway has a key role 
in regulating cell metabolism and is therefore readily hijacked 
by pathogens seeking to acquire energy and control cell death 
for their own propagation. Survival of a pathogen often neces-
sitates that mTOR pathways are either activated or inactivated, 
largely to satisfy particular replication requirements. In turn, 
the counter immune response also varies depending on the type 
and dose of the infecting pathogen. Moreover, mTOR signaling 
varies across responding cell types, cell states, and response 
kinetics. As mTOR senses the immune microenvironment to 
direct cellular activation and differentiation, activity of mTOR 
parallels metabolic activity. Highly glycolytic cells exhibit the 
highest mTOR activity, while lower mTOR activity is associated 
with cells more reliant on oxidative phosphorylation for their 
energy needs (Figure 2). Use of metabolic inhibitors, such as 
rapamycin, that target the mTOR pathway would preferentially 
promote responses by more metabolically inactive Treg, Tfh, and 
memory cells, but would likely do so at the expense of Th1, Th2, 
Th17, CD8 effector, and antibody responses. As most cellular 
responses are intimately linked, opposing outcomes would need 
to be weighed against each other. The outcome of therapeutic 
intervention is also likely to be highly variable depending on 
the nature and stage of infection. Moreover, the precise level 
of mTOR activation is critical for particular immune responses 
as complete inhibition of a pathway can generate very differ-
ent outcomes than partial inhibition. Selectively targeting 
components of the mTOR pathway and metabolic programing 
may prove more effective in designing vaccine strategies. For 
example, suppression of mTORC2 has potential for promoting 
the generation of memory CD8+ T cells, without negatively 
affecting the development of effector CD8+ T cells. The impact 
of any therapeutic approach on the metabolic pathway must be 
thoroughly anticipated and tested as it is clear that there is still 
much to learn about utilizing the mTOR pathway for successful 
therapeutic intervention.
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